Short answer
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). No substantive Item 2.02 earnings information provided.
IRONWOOD PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- No substantive Item 2.02 earnings information provided
- Investors should review the referenced earnings release for fiscal-year 2026 results
Item EX-99.1 · Exhibit EX-99.1
- Raised 2026 guidance: LINZESS U.S. sales $1.15–$1.20B, revenue $460–$485M, adjusted EBITDA above $310M
- Q2 LINZESS sales $282.3M, up 14%, supported by 4% demand growth and improved net pricing
- Q2 revenue $113.0M, GAAP net income $51.3M, adjusted EBITDA $83.0M, all materially above Q2 2025
- Repaid $200M of 1.50% convertible notes at maturity using cash, reducing debt but lowering cash to $79.1M
- STARS-2 Phase 3 apraglutide trial actively recruiting, creating a key pipeline catalyst for short bowel syndrome with intestinal failure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IRONWOOD PHARMACEUTICALS INC 8-K filings
Get the next IRWD 8-K as it lands
Follow IRWD for push alerts, or ask the research agent what this filing means.